HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Høgdall, E. V.S. Articles by Jacobs, I. J. Search for Related Content PubMed PubMed Citation Articles by Høgdall, E. V.S. Articles by Jacobs, I. J. Related Collections Proteomics and Protein Markers Endocrinology and Metabolism

OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage

¹ Laboratory of Molecular Biology, Department of Clinical Biochemistry, State Serum Institute, Artillerivej 5, 2300 Copenhagen, Denmark;
² The Gynaecologic Clinic, The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark DK-2100;
³ Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark DK-2100;
⁴ MD Anderson Cancer Center, Houston, Texas, 77030;
⁵ Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, Denmark DK-8200;
⁶ Gynaecology Cancer Research Unit, Department of Gynaecological Oncology, St. Bartholomew's Hospital, London, UK EC1A 7BE;
^a author for correspondence: fax 0045 3268 3878, e-mail hogdall@dadlnet.dk

OVX1 is a tumor marker that may be of value in the management of ovarian cancer and appears to be complementary to CA125 measurement (1)(2)(3). The results of a study by Woolas et al. (2) suggested that OVX1 is increased in the serum of a major proportion of patients with stage I ovarian cancer who have serum CA125 concentrations within the health-related reference interval. We, therefore, had planned to include OVX1 measurement in a prospective study of screening for ovarian cancer. Because the screening study involved sending blood samples by post to a central laboratory, we undertook this preliminary study to assess the stability of OVX1 in the 2- to 3-day time period required for postal delivery.

All subjects in this study were apparently healthy premenopausal women. Venipuncture was performed on 20 subjects in the UK and 9 subjects in Denmark. The collection tubes, the storage temperature before centrifugation, and the length of storage before centrifugation were varied. All samples were then centrifuged at 2000g for 10 min, and the plasma or serum samples were stored at -20 °C until OVX1 analysis was performed. In addition, to investigate the effect of repetitive thawing and freezing, serum samples from nine subjects were divided into eight aliquots and frozen. After 24 h, seven aliquots from each subject were thawed at room temperature and refrozen after 1 h. This process was repeated daily, leaving one aliquot frozen each day, until the last aliquot was frozen and thawed after 8 day for OVX1 analysis.

The Wilcoxon test was used for paired data. Correlations were examined by linear regression.

The . . . [Full Text of this Article]

Acknowledgments

References

The following articles in journals at HighWire Press have cited this article:

				I. J. Jacobs and U. Menon Progress and Challenges in Screening for Early Detection of Ovarian Cancer Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366. [Abstract] [Full Text] [PDF]